PHILADELPHIA, July 29, 2019 /PRNewswire/ — The 13th Digital Pharma East returns to the Pennsylvania Convention Center on September 17–20. Join us — and more than 1,000 attendees — for four days of interactive learning and networking. Leave the event with a clear business plan for internally justifying digital innovation, budget, and de-risking proposals for commercial success.
We’ve gathered a group of industry experts from Merck, Pfizer, Novartis, GSK, Johnson & Johnson, Sanofi, and many more, with the help of our Advisory Board, to ensure we meet the needs of this community.
New For 2019 Attendees
The agenda is designed to help you understand how you can present business plans, justify budget, innovation and de-risk proposals getting shut down. Essentially, understand how you can return to the office and become a champion for internal digital needs!
Ready to register? Click here and be sure to mention Discount Code 799119PRNEWS for 15% off the standard registration rate! For more information on the program, download the brochure.
For More Information
About Questex
At Questex, we are passionate about driving business outcomes. We connect buyers and sellers and help both achieve their goals. We are online, on devices and live with experiential engagements. We understand the buyer’s behavior and evolving needs and connect them with the seller through continual touchpoints. From discovery through purchase and purchase through advocacy, we supply unmatched access, insight, engagement and turnkey solutions all in one place.
View original content:http://www.prnewswire.com/news-releases/whats-new-for-13th-digital-pharma-east-at-the-pennsylvania-convention-center-300891435.html
SOURCE ExL Events
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…